Darwin AG

Darwin AG maintains a strong liquidity position with a current ratio of 4.05 and cash and equivalents of EUR 20.66 million, indicating the company has sufficient short-term assets to cover its liabilities. The company's price-to-book ratio of 0.99 and price-to-tangible-book ratio of 0.99 suggest that the market value is closely aligned with the book value, indicating a relatively conservative valuation. In terms of profitability, Darwin AG demonstrates a return on equity (ROE) of 17.1% and a return on assets (ROA) of 11.83%, which are strong indicators of efficient use of equity and assets to generate profits. The company's operating income of EUR 18.19 million and net income of EUR 18.10 million reflect a healthy margin, although the gross profit of EUR 10.33 million suggests that the company may be facing competitive pricing pressures. Darwin AG's revenue is primarily concentrated in its core business of biotechnology and AI-based personalized solutions, with no disclosed geographic diversification in the provided data. The company's fully licensed laboratories cover a wide range of genetic and metabolomic testing, which is a key differentiator in the healthcare diagnostics market. The company's growth trajectory is positive, with a strong net income and operating income. However, the operating cash flow is negative at EUR -25.26 million, which may indicate that the company is investing heavily in operations or facing challenges in converting sales into cash. The free cash flow of EUR 16.90 million suggests that the company is generating enough cash to sustain operations and potentially fund growth initiatives. Darwin AG's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The company's debt-to-equity ratio of 0.03 is low, suggesting minimal financial leverage and a conservative capital structure. The company's capital expenditure of EUR -4.34 million indicates that it is not currently investing heavily in new assets, which may be a strategic decision to preserve cash. Recent events and filings do not indicate any significant changes in the company's operations or financial position. The company's mean price target of EUR 26.00 and median price target of EUR 26.00 suggest that analysts have a positive outlook on the company's future performance. The mean recommendation of 1.50, with one strong-buy and one buy rating, further supports this positive sentiment.